Raiffeisen Bank International AG Buys Shares of 20,000 CRISPR Therapeutics AG $CRSP

Raiffeisen Bank International AG acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 20,000 shares of the company’s stock, valued at approximately $1,127,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cerity Partners LLC lifted its holdings in CRISPR Therapeutics by 3.0% in the 2nd quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock worth $318,000 after purchasing an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp increased its stake in CRISPR Therapeutics by 3.0% during the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock valued at $339,000 after acquiring an additional 200 shares during the period. Allworth Financial LP raised its stake in shares of CRISPR Therapeutics by 2.7% in the fourth quarter. Allworth Financial LP now owns 9,550 shares of the company’s stock valued at $501,000 after purchasing an additional 249 shares in the last quarter. Meeder Advisory Services Inc. raised its stake in shares of CRISPR Therapeutics by 6.6% in the 4th quarter. Meeder Advisory Services Inc. now owns 4,392 shares of the company’s stock valued at $230,000 after buying an additional 270 shares in the last quarter. Finally, IFP Advisors Inc lifted its holdings in shares of CRISPR Therapeutics by 29.9% during the 4th quarter. IFP Advisors Inc now owns 1,250 shares of the company’s stock worth $66,000 after acquiring an additional 288 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Trading Down 1.2%

CRISPR Therapeutics stock opened at $55.79 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85. The firm has a 50-day moving average of $53.86 and a 200-day moving average of $52.95. The company has a market cap of $5.39 billion, a price-to-earnings ratio of -11.72 and a beta of 1.76. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The company had revenue of $10.18 million for the quarter. On average, equities analysts expect that CRISPR Therapeutics AG will post -4.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CRSP. Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the company an “equal weight” rating in a research note on Thursday, June 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. Needham & Company LLC reiterated a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a report on Monday, August 31st. Citizens Jmp reiterated a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Finally, HC Wainwright restated a “buy” rating on shares of CRISPR Therapeutics in a report on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $68.06.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.